Westmead Millennium Institute logo

 

 

Professor Jeremy Chapman Professor Jeremy Chapman

Director Acute Interventional Medicine and Renal Services Westmead Hospital, SWAHS

Professor Jeremy Chapman is a renal physician with a special interest in transplantation.  He is Director of Acute Interventional Medicine (SWAHS) and Renal Services at Westmead Hospital, Consultant Medical Director to the NSW Australian Red Cross Blood Service Tissue Typing Laboratory and Chairman of the Australian Bone Marrow Donor Registry, the Australian Cord Blood Bank Network and the Cognate Committee on Organ and Tissue Donation and Transplantation and Past President of the Transplantation Society of Australia and New Zealand.  On a global level he is President of The Transplantation Society, Immediate Past President of the World Marrow Donor Association and Chair of the Global Alliance for Transplantation.

 

Professor Chapman's clinical work is in renal medicine, transplantation of kidney and pancreas and diabetic renal disease and islet transplantation, while he is currently pursuing research interests in transplantation, tissue typing and xenotransplantation.


Professor Chapman is actively involved in the academic field having over 250 clinical papers to his name. He is a Professor at the University of Sydney. He is a Fellow of the Royal College of Physicians in the United Kingdom and a Fellow of the Royal Australasian College of Physicians.

 

Research Interests

Research Interests include:

  • histocompatibility
  • unrelated bone marrow transplantation
  • clinical islet transplantation
  • islet xenotransplantation
  • clinical immunosuppression.
  • cancer after renal transplantation.

 

Back to the top

 

Publications

 

- 2008 - 2007 - 2006 -

 

2008

  • White SL, Chadban SJ, Jan S, Chapman J, Cass, A.  How can we achieve global equity in provision of renal replacement therapy?  Bulletin of the World Health Organization; Policy and Practice Article ID:  07-041715. 2008 Jan. [Abstract]
  • Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado J, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H.  Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.”  J Heart Lung Transplant 2008; 27:141-9. [Abstract]
  • Wong G, Howard K, Craig JC, Chapman JR.  Cost-effectiveness of colorectal cancer screening in renal transplant recipients.  Transplantation.  2008 Feb 27; 85 (4):532-41. [Abstract]
  • Wong G, Chapman JR, Craig JC.  Cancer screening in renal transplant recipients:  what is the evidence?  Clin J Am Soc Nephrol.  2008 Mar;3 Suppl2:S87-S100. [Abstract]
  • White SL, Chadban SJ, Jan S, Chapman JR, Cass A.  How can we achieve global equity in provision of renal replacement therapy?  Bull WHO. 2008 Mar; 86(3):229-37. [Abstract]
  • Chapman JR, Allen RD.  Paired kidney exchange: how far and how wide?  Transplantation.  2008 Mar 15;85(5):673-4. [Abstract]
  • Wong G, Chapman JR.  Cancers after renal transplantation.  Transplant Rev (Orlando).  2008 Apr;22 (2):141-9. [Abstract]
  • Chapman JR.  Introduction: targets for improving outcomes in renal allografts transplanted during the next ten years.  Transplantation.  2008 Apr 15;85 (7 Suppl):S1-2. [Abstract]
  • Burke JT, Brault Y, Kahan BD, Hricik DE, Ginyo JM, Chapman JR, Polinsky M, Neylan JF.  Accuracy and variability in equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.  Transpl Int.  2008 May;21 (5):434-40. [Abstract]
  • Chapman J.  Should we pay donors to increase the supply of organs for transplantation?  No.  BMJ.  2008 Jun 14:336(7657):1343 [Abstract]
  • Shinozaki N, Holland E, Kearney J, Kurz J, Chapman J.  Global coding system for human cells and tissues for transplantation.  Transplantation.  2008 Jul 15;86(1). [Abstract]
  • Seron D, Arns W, Chapman JR.  Chronic allograft nephropathy—clinical guidance for early detection and early intervention strategies.  Nephrol Dial Transplant. 2008 Aug;23(8):2467-73. [Abstract]
  • Vitalone MJ, O’Connell PJ, Jimenez-Vera E, Yuksel A, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ.  Epithelial-to-mesenchymal transition in early transplant tubulointerstital damage.  JASN.  2008 Aug;19(8):1571-83. [Abstract]
  • Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA, Cantarovich D, Cathro HP, Chapman J, Dimosthenous K, Fyfe-Kirschner B, Gaber L, Gaber O, Goldberg J, Honsová E, Iskandar SS, Klassen DK, Nankivell B, Papadimitriou JC, Racusen LC, Randhawa P, Reinholt FP, Renaudin K, Revelo PP, Ruiz P, Torrealba JR, Vazquez-Martul E, Voska L, Stratta R, Bartlett ST, Sutherland DE. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant. 2008 Jun;8(6):1237-49. [Abstract]
  • International Summit on Transplant Tourism and Organ Trafficking. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Clin J Am Soc Nephrol. 2008 Sep;3(5):1227-31. [Abstract]
  • Commentary. Organ Trafficking and Transplant Tourism and Transplant Tourism. The Declaration of Istanbul. The steering committee of The Declaration of Istanbul. Lancet 2008; 372: 5-6.

 

Back to the top

 

2007

  • Nankivell BJ, Wavamuno MD, Borrows RJ, Vitalone M, Fung CLS, Allen RDM, Chapman JR, O’Connell PJ.  Mycophenolate Mofetil Is Associated with Altered Expression of Chronic Renal Transplant Histology.  AJT 2007 Feb; 7(2):366-376. [Abstract]
  • Mengel M, Chapman JR, Cosio FG, Cavaille-Coll MW, Haller H, Halloran PF, Kirk AD, Mihatsch MJ, Nankivell BJ, Racusen LC, Roberts IS, Rush DN, Schwarz A, Seron D, Stegall MD, Colvin RB.  Protocol biopsies in renal transplantation: insights into patient mangement and pathogenesis.  AJT.  2007 Mar; 7(3):512-7. [Abstract]
  • Abbud-Filho M, Adams PL, Alberú J, Cardella C, Chapman J, Cochat P, Cosio F, Canovitch G, Davis C, Gaston RS, Humar A, Hunsicker LG, Josephson MA, Kasiske B, Kirste G, Leichtman A, Munn S, Obrador GT, Tibell A, Wadström J, Zeier M, Delmonico FL.  A report of the Lisbon Conference on the care of the kidney transplant recipient.  Transplantation.  2007 Apr 27;83(8 Suppl):S1-22.  [Abstract]
  • Campistol JM, Albanell J, Arns W, Voletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Oyen O, Pascual J, Pohanka E, Schena FP, Seron D, Sparacino V, Chapman JR.  Use of proliferation signal inhibitors in the management of post-transplant malignancies — clinical guidance.  Nephrol Dial Transplant. 2007 May;22 Suppl 1:i36-41.  Review. [Abstract]
  • Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR.  Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients.   AJT.  2007 Sep;7(9):2140-51. [Abstract]
  • Vajdic CM, van Leeuwen MT, McDonald SP, McCredie MR, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE.  Increased incidence of squamous cell carcinoma of eye after kidney transplantation.  J Natl Cancer Inst.  2007 Sep 5; 99(17):1340-2. [Abstract]
  • Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, MOta A, Grandaliano G, Campistol JM, Brault Y, Burke JT; for the Rapamune Maintenance Regimen (RMR) Study Group.  Incidence of anemia in sirolimus-treated renal transplant recipients:  the importance of preserving renal function.  Transpl Int 2007 Sep:20(9):754-60. [Abstract]
  • Samuel GN, Kerridge IH, Vowels M, Trickett A, Chapman J, Dobbins T.  Ethnicity, equity and public benefit:  a critical evaluation of public umbilical cord blood banking in Australia.  Bone Marrow Transplant.  2007 Oct;63(40):E95-9. [Abstract]
  • Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A.  Proliferation signal inhibitors in transplantation:  questions at the cutting edge of everolimus therapy.  Transplant Proc. 2007 Dec: 39(10):2937-50. [Abstract]
  • Butterworth BE, Chapman JR.  Exposure of hematopoietic stem cells to ethylene oxide during processing represents a potential carcinogenic risk for transplant recipients.  Regul Toxicol Pharmacol. 2007 Dec: 49(3): 149-53. [Abstract]
  • Wavamunno MD, O’Connell PJ, Vitalone M, Fung CL, Allen RD, Chapman JR, Nankivell BJ.  Transplant glomerulopathy:  ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies.  AJT. 2007 Dec;7(12):2757-68. [Abstract]

 

Back to the top

 

 

2006

  • Salvadori M, Rosati A, Bock A, Chapman JR, Dussol B, Fritsche L, Kleim V, Lebranchu Y, Oppenheimer F, Pohanka E, Tufveson G, Bertoni E.  Estimated One-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant.  Transplantation 2006; 81 (2), 202- 206. [Abstract]
  • O’Connell PJ, Hawthorne WJ, Holmes-Walker D J, Nankivell BJ, Gunton JE, Patel AT, Walters SN, Pleass HCC, Allen RDM, Chapman JR.  Clinical islet transplantation in type 1 diabetes mellitus: results of Australia’s first trial.  MJA 2006 Mar; 184 (5) 221 – 225. [Abstract]
  • Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006 Mar. 81(5):643-54. [Abstract]
  • Groth CG, Chapman JR.  The global alliance for transplantation. Transplant Proc 2006 Mar.  38(2):356-7. [Abstract]
  • Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC.  Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients:  a systematic review of randomized trial data.  Transplantation, 2006 Apr.  15; 81(7):953-65. [Abstract]
  • Chapman JR.  Not all donors are equal.  Transplantation 2006 Apr.  15;81 (7):976-7. [Abstract]
  • Webster AC, Lee VW, Chapman JR, Craig JC.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kideny transplant recipients.  Cochrane Database Syst Rev 2006 Apr.  19; (02):CD004290. [Abstract]
  • Webster A, Pankhurst T, Rinaldi F, Chapman JR, Craig JC.  Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.  Cochrane Database Sys Rev 2006 Apr. 19;(2):CD004756. [Abstract]
  • Webster AC, Lee VW, Chapman JR, Craig JC.  Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients:  a systematic review and meta-analysis of randomized trials.  Transplantation 2006 May.  15;81 (9): 1234-48. [Abstract]
  • Goddard K, Pleass H, Cross N, O’Connell P, Chapman J, Nankivell B, Allen R.  A twist of fate or fated to twist?  Immunology & Cell Biology, 2006 June; 83 (3):A6.
  • Chapman JR, Nankivell BJ.  Nephrotoxicity of Cyclosporin A – short term gain, long term pain?  NDT 2006. [Abstract]
  • Kee TYS, Chapman JR, O’Connell PJ, Fung CLS, Allen RDM, Kable K, Vitalone MJ, Nankivell BJ.  Treatment of subclinical Rejection Diagnosed by Protocol Biopsy of Kidney Transplants.  Transplantation 2006 July. 82: 36 – 42. [Abstract]
  • Chapman J.  Guest Editor’s Introduction.  Managing cardiovascular risk in renal transplant recipients:  the role of everolimus.  NDT 2006 Jul.  21 (3): iii1-iii2. Editor.
  • Nankivell BJ, Chapman JR.  The significance of subclinical rejection and the value of protocol biopsies.  AJT 2006; (6): 2006 – 2012. [Abstract]
  • Mathew TH, Chapman JR.  Organ donation:  a chance for Australia to do better.  Med J Aust. 2006 Sep; 185(5):245-6. [Abstract]
  • Chapman J, Bock A, Dussol B, Fritsche L, Kliem V, Lebranchu Y, Oppenheimer F, Pohanka E, Rosati A, Salvadori M, Tufveson G.  Follow-up after renal transplantation with organs from donors after cardiac death. Transplant Int.  2006 Sept. 19 (9): 715-719. [Abstract]
  • Chapman J.  Scoring arteriolar hyalinosis in renal allograft biopsies:  so important yet so tricky.  Nature Clinical Practice Nephrology 2006 Nov. 2 (11): 622 - 623 . [Abstract]
  • Vajdic, CM, McDonald SP, McCredie MRE, Van Leeuwen MT, Stewart JH, Law M. Chapman JR, Webster AC, Kaldor JM, Grulich AE.  Cancer Incidence Before and After Kidney Transplantation.  JAMA 2006 Dec; 296 (23): 2823-31. [Abstract]

 

Back to the top

 

Contact details

T +61 2 9845 6349
F +61 2 9633 8300
E Jeremy_Chapman@wsahs.nsw.gov.au

 

Back to the top

 

 

 

 

 

 

 

 

 

 

| Home | About Us | Research | Our People | The Millennium Foundation | News & Events | Contact Us | Search |

 

© 2000-2008 Westmead Millennium Institute